Organisation: Boston District Office of the Securities and Exchange Commission

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Biogen confirms securities law probe

BIOGEN IDEC INC yesterday said US securities regulators are formally probing whether there were any violations of securities laws related to suspension of its multiple sclerosis drug Tysabri.

Sat, 30 Apr, 2005

Organisation: Boston District Office of the Securities and Exchange Commission

Biogen confirms securities law probe

Latest

Mick Clifford

Organisation: Boston District Office of the Securities and Exchange Commission

Biogen confirms securities law probe

Latest

Mick Clifford

Most Read